Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells

Journal of Gene Medicine

Volumn 16, Issue 5-6, 2014, Pages 131-142

  Dodd, Megan ^a,b   Marquez Curtis, Leah ^c   Janowska Wieczorek, Anna ^c,d   Hortelano, Gonzalo ^a,e  

^a MCMASTER UNIVERSITY   (Canada)

^b Department of Biomedical Engineering Jimma Institute of Technology   (Ethiopia)

^c CANADIAN BLOOD SERVICES   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e NAZARBAYEV UNIVERSITY   (Kazakhstan)

Author keywords

Coagulation factor IX; Hemophilia B; Lentiviral vector; Mesenchymal stromal cells

Indexed keywords

LENTIVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9;

ADIPOCYTE; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSPLANTATION; CONTROLLED STUDY; CORD BLOOD DERIVED MESENCHYMAL STROMAL CELL; DNA VECTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; MESENCHYMAL STROMA CELL; OSTEOBLAST; PRIORITY JOURNAL; RESTRICTION MAPPING; STABLE EXPRESSION; UMBILICAL CORD BLOOD; VIRAL GENE DELIVERY SYSTEM; ADIPOGENESIS; ANIMAL; CELL CULTURE; CELL LINE; CHONDROGENESIS; CYTOLOGY; FETUS BLOOD; GENE EXPRESSION; GENE ORDER; GENE VECTOR; GENETICS; HEMOPHILIA B; LENTIVIRINAE; METABOLISM; MOUSE; PARTIAL THROMBOPLASTIN TIME;

ADIPOGENESIS; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; CHONDROGENESIS; FACTOR IX; FETAL BLOOD; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HEMOPHILIA B; HUMANS; LENTIVIRUS; MESENCHYMAL STROMAL CELLS; MICE; PARTIAL THROMBOPLASTIN TIME; TRANSDUCTION, GENETIC;

EID: 84904563461     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2769     Document Type: Article

References (77)

1. Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. Front Immunol 2013; 4: 201.
2. Chinnadurai R, Waller EK, Galipeau J, Nooka AK. From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. Biomed Res Int 2013; 2013. doi:10.1155/2013/929842.
3. Olson SD, Pollock K, Kambal A, et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for huntington's disease. Mol Neurobiol 2012; 45: 87-98.
4. Wyse RD, Dunbar GL, Rossignol J. Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci 2014; 15: 1719-1745.
5. Doering CB, Archer D, Spencer HT. Delivery of nucleic acid therapeutics by genetically engineered haematopoietic stem cells. Adv Drug Deliv Rev 2010; 62: 1204-1212.
6. Petrus I, Chuah M, VandenDriessche T. Gene therapy strategies for haemophilia: benefits versus risks. J Gene Med 2010; 12: 797-809.
7. Liras A. Induced human pluripotent stem cells and advanced therapies: future perspectives for the treatment of haemophilia? Thromb Res 2011; 128: 8-13.
8. Coutu DL, Cuerquis J, El Ayoubi R, et al. Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of haemophilia B. Biomaterials 2011; 32: 295-305.
9. Wang JJ, Kuang Y, Zhang LL, et al. Phenotypic correction and stable expression of factor VIII in haemophilia A mice by embryonic stem cell therapy. Genet Mol Res 2013; 12: 1511-1521.
10. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
11. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 1994; 56: 283-294.
12. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74.
13. Pittenger MF. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
14. Zhang HT, Liu ZL, Yao XQ, Yang ZJ, Xu RX. Neural differentiation ability of mesenchymal stromal cells from bone marrow and adipose tissue: a comparative study. Cytotherapy 2012; 14: 1203-1214.
15. Son B-R, Marquez-Curtis LA, Kucia M, et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006; 24: 1254-1264.
16. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012; 67: 1-8.
17. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp haematol 2002; 30: 42-48.
18. Prockop DJ, Youn OJ. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012; 20: 14-20.
19. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
20. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
21. Krampera M, Sartoris S, Liotta F, et al. Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev 2007; 16: 797-810.
22. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp haematol 2001; 29: 244-255.
23. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002; 99: 8932-8937.
24. Koç ON, Gerson SL, Cooper BW, et al. Rapid haematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-316.
25. Chapel A, Bertho JM, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co-infused with haematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003; 5: 1028-1038.
26. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumour microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008; 15: 730-738.
27. Marquez-Curtis LA, Janowska-Wieczorek A. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis. Biomed Res Int 2013; 2013. doi:10.1155/2013/561098.
28. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse haematopoietic organs. Exp haematol 1976; 4: 267-274.
29. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109: 235-242.
30. Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-634.
31. Lee JY, Qu-Petersen Z, Cao B, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol 2000; 150: 1085-1100.
32. Brighton CT, Lorich DG, Kupcha R, Reilly TM, Jones AR, Woodbury RA. The pericyte as a possible osteoblast progenitor cell. Clin Orthop Relat Res 1992; 275: 287-299.
33. Toma JG, Akhavan M, Fernandes KJ, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001; 3: 778-784.
34. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-228.
35. Helledie T, Nurcombe V, Cool SM. A simple and reliable electroporation method for human bone marrow mesenchymal stem cells. Stem Cells Dev 2008; 17: 837-848.
36. Satija NK, Singh VK, Verma YK, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med 2009; 13: 4385-4402.
37. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008; 3: e2213.
38. Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
39. Naldini L, Blömer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-11388.
40. Van Damme A, Thorrez L, Ma L, et al. Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells 2006; 24: 896-907.
41. Segura MM, Mangion M, Gaillet B, Garnier A. New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 2013; 13: 987-1011.
42. Hu WS, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev 2000; 52: 493-511.
43. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68: 510-516.
44. Follenzi A, Santambrogio L, Annoni A. Immune responses to lentiviral vectors. Curr Gene Ther 2007; 7: 306-315.
45. Federico M. Lentiviruses as gene delivery vectors. Curr Opin Biotechnol 1999; 10: 448-453.
46. Piacibello W, Bruno S, Sanavio F, et al. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Blood 2002; 100: 4391-4400.
47. Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007; 36: 184-204.
48. Verhoeyen E, Cosset FL. Surface-engineering of lentiviral vectors. J Gene Med 2004; 6: S83-S94.
49. Zhang X-Y, La Russa VF, Bao L, Kolls J, Schwarzenberger P, Reiser J. Lentiviral vectors for sustained transgene expression in human bone marrow-derived stromal cells. Mol Ther 2002; 5: 555-565.
50. Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996; 70: 2581-2585.
51. Totsugawa T, Kobayashi N, Okitsu T, et al. Lentiviral transfer of the LacZ gene into human endothelial cells and human bone marrow mesenchymal stem cells. Cell Transplant 2002; 11: 481-488.
52. Zhang X-Y, La Russa VF, Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J Virol 2004; 78: 1219-1229.
53. Chang AH, Stephan MT, Lisowski L, Sadelain M. Erythroid-specific human factor IX delivery from in vivo selected haematopoietic stem cells following nonmyeloablative conditioning in haemophilia B mice. Mol Ther 2008; 16: 1745-1752.
54. Deuse T, Peter C, Fedak PWM, et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009; 120: S247-S254.
55. Fan L, Lin C, Zhuo S, et al. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur J Heart Fail 2009; 11: 1023-1030.
56. Lian WS, Cheng WTK, Cheng CC, et al. In vivo therapy of myocardial infarction with mesenchymal stem cells modified with prostaglandin I synthase gene improves cardiac performance in mice. Life Sci 2011; 88: 455-464.
57. McGinley L, McMahon J, Strappe P, et al. Lentiviral vector mediated modification of mesenchymal stem cells and enhanced survival in an in vitro model of ischaemia. Stem Cell Res Ther 2011; 2: 12.
58. Zou D, Han W, You S, et al. In vitro study of enhanced osteogenesis induced by HIF-1alpha-transduced bone marrow stem cells. Cell Prolif 2011; 44: 234-243.
59. Yu Y-S, Shen Z-Y, Ye W-X, et al. AKT-modified autologous intracoronary mesenchymal stem cells prevent remodelling and repair in swine infarcted myocardium. Chin Med J (Engl) 2010; 123: 1702-1708.
60. Ricks DM, Kutner R, Zhang X-Y, Welsh DA, Reiser J. Optimized lentiviral transduction of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev 2008; 17: 441-450.
61. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872.
62. Pfeifer A, Ikawa M, Dayn Y, Verma IM. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci U S A 2002; 99: 2140-2145.
63. Ma Y, Ramezani A, Lewis R, Hawley RG, Thomson JA. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells 2003; 21: 111-117.
64. Hortelano G, Xu N, Vandenberg A, Solera J, Chang PL, Ofosu FA. Persistent delivery of factor IX in mice: gene therapy for haemophilia using implantable microcapsules. Hum Gene Ther 1999; 10: 1281-1288.
65. Wen J, Vargas AG, Ofosu FA, Hortelano G. Sustained and therapeutic levels of human factor IX in haemophilia B mice implanted with microcapsules: key role of encapsulated cells. J Gene Med 2006; 8: 362-369.
66. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
67. Higashimoto T, Urbinati F, Perumbeti A, et al. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther 2007; 14: 1298-1304.
68. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101: 173-185.
69. Sirven A, Pflumio F, Zennou V, et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human haematopoietic stem cells. Blood 2000; 96: 4103-1410.
70. Cochrane AW, Chen CH, Rosen CA. Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA. Proc Natl Acad Sci U S A 1990; 87: 1198-202.
71. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010; 467: 318-322.
72. Sayyar B, Dodd M, Marquez-Curtis L, Janowska-Wieczorek A, Hortelano G. Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. fibrinogen-alginate microcapsules. Artif Cells Nanomed Biotechnol 2014; 42: 102-109.
73. Sayyar B, Dodd M, Wen J, et al. Encapsulation of factor IX-engineered mesenchymal stem cells in fibrinogen-alginate microcapsules enhances their viability and transgene secretion. J Tissue Eng 2012; 3 doi 10.1177/2041731412462018.
74. Vinatier C, Bouffi C, Merceron C, et al. Cartilage tissue engineering: towards a biomaterial-assisted mesenchymal stem cell therapy. Curr Stem Cell Res Ther 2009; 4: 318-329.
75. Panetta NJ, Gupta DM, Quarto N, Longaker MT. Mesenchymal cells for skeletal tissue engineering. Panminerva Med 2009; 51: 25-41.
76. Lindemann C, Schilz AJ, Emons B, et al. Down-regulation of retroviral transgene expression during differentiation of progenitor-derived dendritic cells. Exp haematol 2002; 30: 150-157.
77. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005; 16: 1241-1246.